Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Radiotherapy for newly diagnosed malignant glioma in adults: a clinical practice guideline.

BIBLIOGRAPHIC SOURCE(S)

  • Laperriere N, Perry J, Zuraw L, Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2005 Nov 2. 32 p. (Evidence-based series; no. 9-3). [87 references]

GUIDELINE STATUS

BRIEF SUMMARY CONTENT

 RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

  • Postoperative external beam radiotherapy is recommended as standard therapy.
  • The high-dose volume should incorporate the enhancing tumour plus a limited margin (e.g., 2 cm) for the planning target volume, and the total dose delivered should be 60 Gy in 2 Gy fractions, with concurrent temozolomide at 75 mg/m2.
  • Radiation dose intensification and radiation sensitizer approaches are not recommended as standard care.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The recommendations are supported by randomized controlled trials and meta-analyses.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Laperriere N, Perry J, Zuraw L, Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2005 Nov 2. 32 p. (Evidence-based series; no. 9-3). [87 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2000 Sep 19 (revised 2005 Nov 2)

GUIDELINE DEVELOPER(S)

Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]

GUIDELINE DEVELOPER COMMENT

The Program in Evidence-based Care (PEBC) is a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

SOURCE(S) OF FUNDING

Cancer Care Ontario
Ontario Ministry of Health and Long-Term Care

GUIDELINE COMMITTEE

Provincial Neuro-oncology Disease Site Group

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

The following is available:

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on May 14, 2004. The information was verified by the guideline developer on June 2, 2004. This NGC summary was updated by ECRI on September 27, 2004. The updated information was verified by the guideline developer on October 20, 2004. This NGC summary was updated on June 8, 2006. The updated information was verified by the guideline developer on June 26, 2006.

COPYRIGHT STATEMENT

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo